申请人:Pfizer Inc.
公开号:US04176185A1
公开(公告)日:1979-11-27
Novel spiro-quinolylhydantoin derivatives useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Preferred compounds include spiro[imidazolidin-4,4'-pyrano[3,2-h]quinolin]-2,5-dione and spiro[imidazolidin-4,4'-pyrano[2,3-f]quinolin]-2,5-dione.
揭示了作为醛糖还原酶抑制剂和治疗慢性糖尿病并发症的治疗剂的新型螺环喹诺基噁唑基恒丹类衍生物。首选化合物包括螺[咪唑啉-4,4'-吡喃[3,2-h]喹啉]-2,5-二酮和螺[咪唑啉-4,4'-吡喃[2,3-f]喹啉]-2,5-二酮。